EyeGate Pharma (Waltham, MA) a pharmaceutical company pioneering the use of iontophoresis technology to deliver therapeutics for ocular indications, announced that it has closed on a $2M extension of its Series B, bringing the total of the financing to $12M. This funding comes from the Nexus Group, the round was originally led by Innoven Partenaires and Ventech.
OnBioVC
From the A to the Exit: What is Happening in Bio VC
I’m Going to BioWest!
Are You?
